NDA 021585 · Reckitt Benckiser
Mucinex D
Guaifenesin, Pseudoephedrine Hydrochloride · Oral · Expectorant
Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jun 22, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
147
31 Phase 3, 6 recruiting
FAERS reports
1,816
694 serious, 58 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 27, 2026.
Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- MUCINEX D · GUAIFENESIN 600MG; PSEUDOEPHEDRINE HYDROCHLORIDE 60MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
- MUCINEX D · GUAIFENESIN 1.2GM; PSEUDOEPHEDRINE HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Guaifenesin" as an intervention, any sponsor and status, largest first.
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract InfectionsPivotal-lookingCompleted
Reckitt Benckiser LLCIndustry
NCT01537081 · 2,810 participants · Start Sep 2011 · Primary completion Mar 2012
Drug: Mucinex; Immediate-release Guaifenesin and 1 more · For: Acute Upper Respiratory Tract Infection
Sites: Hoover, Alabama; Bell Gardens, California; Harbor City, California · 43 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTIPivotal-lookingCompleted
Reckitt Benckiser Inc.Industry
NCT01202279 · 1,179 participants · Start Oct 2009 · Primary completion Apr 2010
Drug: Guaifenesin · For: Acute Upper Respiratory Track Infection
Sites: Mesa, Arizona; Carmichael, California; Fresno, California · 24 sites in all
- Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori InfectionPivotal-lookingCompleted
Phathom Pharmaceuticals, Inc.Industry
NCT04167670 · 1,046 participants · Start Dec 10, 2019 · Primary completion Mar 10, 2021
Drug: Vonoprazan; Amoxicillin and 2 more · For: Helicobacter Pylori Infection
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 153 sites in all
- Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After HepatectomyPivotal-lookingStatus unknown
Shuqun ChengAcademic, hospital or other
NCT02399033 · 1,000 participants (planned) · Start Jun 2014 · Primary completion Jul 2019
Drug: Xihuang Capsules · For: Hepatocellular Carcinoma
Sites: Shanghai, China
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple TherapiesPivotal-lookingCompleted
Kaohsiung Veterans General Hospital.Academic, hospital or other
NCT03779074 · 918 participants · Start Sep 3, 2018 · Primary completion Dec 31, 2021
Drug: 10d bismuth quadruple therapy; 14d hybrid therapy and 1 more · For: Helicobacter Pylori Infection
Sites: Kaohsiung City, Taiwan
- Fixed Dose MMF vs Concentration Controlled MMF After Renal TransplantationPivotal-lookingCompleted
Erasmus Medical CenterAcademic, hospital or other
NCT00166244 · 901 participants · Start May 2003 · Primary completion Mar 2005
Drug: Mycophenolate Mofetil · For: De Novo Renal Transplant Recipient.
Sites: New Lambton, Australia; Brisbane, Australia; Clayton, Australia · 67 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective147
- insomnia146
- dizziness129
- headache112
- nausea108
- fatigue105
- dyspnoea85
- accidental overdose76
- cough72
- sinusitis71
- diarrhoea69
- pain68
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 20 |
| 2010 | 58 |
| 2011 | 34 |
| 2012 | 52 |
| 2013 | 78 |
| 2014 | 59 |
| 2015 | 132 |
| 2016 | 227 |
| 2017 | 223 |
| 2018 | 175 |
| 2019 | 147 |
| 2020 | 151 |
| 2021 | 57 |
| 2022 | 96 |
| 2023 | 96 |
| 2024 | 87 |
| 2025 | 79 |
| 2026 | 26 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effect of oral guaifenesin on pediatric chronic rhinitis: A pilot study.
Dodson KM, Indeyeva YA, Ma J, et al. · Am J Otolaryngol 2023 · Randomized Controlled Trial
- Over-the-counter (OTC) medications for acute cough in children and adults in community settings.
Smith SM, Schroeder K, Fahey T · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV).
Wawrose SF, Tami TA, Amoils CP · Laryngoscope 1992 · Clinical Trial, Randomized Controlled Trial
- Evaluation of total intravenous anesthesia with propofol-guaifenesin-medetomidine and alfaxalone-guaifenesin-medetomidine in Thoroughbred horses undergoing castration.
Aoki M, Wakuno A, Kushiro A, et al. · J Vet Med Sci 2017 · Randomized Controlled Trial
- Ephedrine- and guaifenesin-induced nephrolithiasis.
Bennett S, Hoffman N, Monga M · J Altern Complement Med 2004 · Systematic Review
- Comparison of thiopentone/guaifenesin, ketamine/guaifenesin and ketamine/midazolam for the induction of horses to be anaesthetised with isoflurane.
Gangl M, Grulke S, Detilleux J, et al. · Vet Rec 2001 · Clinical Trial, Comparative Study
Sponsor: Reckitt Benckiser
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.